Progress in Pediatric Therapeutics Bigger Than “Smaller Dose”

June 2, 2017

Developing therapies to meet the needs of children has always featured unique challenges, including and especially clinical trials. But due, at least in part, to the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) in the US and the Paediatric Regulation in the EU, much progress has been made. Recap this progress at the DIAmond session Progress in Pediatric Therapeutics, chaired by Dr. Ronald Portman, Executive Director, Pediatric Therapeutic Area for Novartis Pharmaceuticals Corporation, at our DIA 2017 Global Annual Meeting. “As a parent, you want a drug that is being given to your child to have been fully evaluated in the pediatric population – but your initial feeling is, evaluated in somebody else’s child, not mine,” Dr. Portman explains in this exclusive Global Forum podcast. “We as a society have a lot of work to do in educating parents that doing drug development through research is actually very beneficial to their child, and not only their child but children in the future. ” Register for our DIA 2017 Global Annual Meeting in Chicago!


Facebook Comments: